Article info

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
Free

Authors

  • Colleen GC McGregor Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Alex Adams Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Ross Sadler Department of Laboratory Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK PubMed articlesGoogle scholar articles
  • Carolina V Arancibia-Cárcamo Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Rebecca Palmer Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Tim Ambrose Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Oliver Brain Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Alissa Walsh Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Paul Klenerman Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Simon PL Travis Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Nicholas M Croft Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UKDepartments of Gastroenterology and Paediatric Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • James O Lindsay Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UKDepartments of Gastroenterology and Paediatric Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Jack Satsangi Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Colleen GC McGregor, Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford OX3 9DU, UK; colleen.mcgregor{at}ndm.ox.ac.uk
View Full Text

Citation

McGregor CG, Adams A, Sadler R, et al
Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic

Publication history

  • Received January 13, 2021
  • Revised February 2, 2021
  • Accepted February 3, 2021
  • First published February 12, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.